Digital Mammography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The digital mammography market size is expected to grow from USD 2.46 billion in 2025 to USD 2.70 billion in 2026 and is forecast to reach USD 4.30 billion by 2031 at 9.75% CAGR over 2026-2031. This report is Segmented by Product Type (Digital Systems, 3-D Breast Tomosynthesis Systems, and More), Technology (2-D FFDM, 3-D DBT, and More), Application (Screening, Diagnostic, and More), End User (Hospitals, Diagnostic Imaging Centers, and More), and Geography (North America, Europe, Asia-Pacific, Latin America, MEA). Forecasts are Provided in Terms of Value (USD).

Global Digital Mammography Market Trends and Insights

USPSTF Age-40 Screening Expansion Adds a Structural Volume Floor

In April 2024, the U.S. Preventive Services Task Force (USPSTF) extended biennial screening mammography to women aged 40 to 74, marking a significant shift in demand for the digital mammography market. Starting screenings at age 40 could save 20% more lives compared to the previous starting age of 50, with a larger benefit for Black women, who face a 40% higher mortality rate from breast cancer than White women. With a Grade B rating, employer health plans must provide first-dollar coverage, encouraging women in their 40s to undergo routine screenings under the Affordable Care Act. Younger screening cohorts, often with dense breast tissue, increase the operational value of Digital Breast Tomosynthesis (DBT) and AI-enhanced workflows, creating a stable volume floor for the market.

2-D to 3-D DBT Replacement Cycle Accelerates Across High-Income Markets

The digital mammography market is driven by an ongoing replacement cycle among 2-D full-field digital mammography systems. As of March 2025, 8,266 of 8,963 certified facilities in the United States had at least one accredited DBT unit, while 13,759 accredited 2-D units still slightly outnumbered 12,780 DBT units, highlighting significant upgrade potential. DBT is increasingly preferred for organized screenings due to its ability to reduce recalls and improve reading efficiency. Vendors offering modular upgrades instead of full replacements are well-positioned, especially in public systems and community hospitals seeking modernization without overhauling capital plans.

Capital Budget Competition Slows Multi-Modality Upgrade Cycles

Despite favorable demand, the digital mammography market faces capital allocation challenges within health systems. Mammography platforms compete with CT, MRI, and PET/CT for limited budgets, a trend that has intensified since 2024 as providers manage debt, infrastructure upgrades, and service expansions. The high lifecycle costs of DBT platforms make procurement decisions reliant on reimbursement clarity and multi-year budgets rather than clinical preferences. Facilities in rural and emerging areas experience slower upgrades due to additional costs like room shielding, power stability, and PACS connectivity, which often exceed the scanner price. While demand remains strong, these factors extend replacement cycles and push upgrades into long-term planning.

Other drivers and restraints analyzed in the detailed report include:

• Dense-Breast Notification and Follow-Up Imaging Push Drives Incremental Scan Volume
• AI-Enabled Throughput and Recall Reduction Redefines Radiologist Capacity
• Breast-Imaging Workforce Shortage Creates a Structural Capacity Ceiling

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Digital Systems dominated the product-type revenue, claiming a substantial 60.45% share. This shift underscores the digital mammography market's decisive pivot away from its analog roots and retrofit-heavy configurations, especially in advanced imaging systems. Despite a significant installed base still featuring 2-D platforms, replacement demand remains robust in mature markets. C

3-D Breast Tomosynthesis Systems are on a rapid ascent, projected to grow at an 11.25% CAGR through 2031. Their momentum is bolstered by clinical validation, policy backing, and sound procurement rationale. As of March 2025, FDA data highlighted 12,780 accredited DBT units in the U.S., still trailing behind the 13,759 accredited 2-D digital units. This gap underscores the ongoing upgrade cycle. Facilities are increasingly drawn to DBT for its promise of fewer recalls and enhanced performance, especially in dense-breast demographics.

In 2025, 2-D Full-Field Digital Mammography accounted for a significant 50.9% of technology revenue, underscoring the continued reliance on legacy digital systems for near-term procedures. This stronghold is bolstered by a widespread installed base in community and rural facilities, coupled with the operational familiarity and reimbursement of 2-D procedures in various markets. Concurrently, AI-driven CAD and image triage are enhancing both 2-D and DBT hardware performance, allowing for improvements without immediate hardware upgrades.

Photon-counting Digital Mammography is set to chart a robust trajectory, with projections indicating a 10.45% CAGR through 2031, marking it as the most rapidly advancing technology segment. Its allure lies in its detector architecture, which champions dose efficiency and spectral imaging. This ensures heightened sensitivity for detecting small invasive cancers and ductal carcinoma in situ, making it particularly relevant for younger screening demographics and sophisticated contrast workflows. Internationally, there's a burgeoning interest, with early installations and clinical applications in several European and Asian markets signaling a shift from mere trial-stage curiosity.

Complete Report Scope:

• By Product Type
  • Digital Systems
  • 3-D Breast Tomosynthesis Systems
  • Contrast-Enhanced Mammography Systems
  • Computed-Radiography Retrofit Kits
• By Technology
  • 2-D Full-Field Digital Mammography
  • 3-D Digital Breast Tomosynthesis
  • AI-enabled CAD and Image Triage
  • Photon-counting Digital Mammography
• By Application
  • Screening
  • Diagnostic
  • Interventional and Biopsy Guidance
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgical Centers
  • Office-based and Specialty Breast Centers
  • Mobile Screening Programs
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 61.11% of global revenue in 2025, driven by robust federal funding. North America holds the largest share of the digital mammography market, driven by well‑established breast cancer screening programs, strong reimbursement frameworks, and rapid adoption of advanced technologies like 3D tomosynthesis and AI‑assisted diagnostics. The U.S., in particular, benefits from FDA approvals and insurance coverage that encourage hospitals and imaging centers to upgrade from analog to digital systems. High awareness levels and government initiatives further reinforce market dominance, though equipment costs remain a challenge for smaller clinics.

Europe represents a mature market with widespread adoption supported by national screening programs in countries such as Germany, France, and the UK. The region emphasizes early detection and quality standards, with structured reimbursement policies ensuring accessibility.

The Middle East is an emerging market for digital mammography, with countries like Saudi Arabia and the UAE investing heavily in modern diagnostic infrastructure. Growth is fueled by rising breast cancer incidence, government‑backed awareness campaigns, and partnerships with international healthcare providers.

List of Companies Covered in this Report:

• Canon
• CureMetrix, Inc.
• DeepHealth, Inc.
• Delphinus Medical Technologies, Inc.
• Densitas, Inc.
• FUJIFILM
• GE Healthcare
• General Medical Merate
• Hologic
• iCAD, Inc.
• Konica Minolta
• Lunit
• Metaltronica
• Onsite Women's Health, LLC
• Planmed
• RadNet, Inc.
• ScreenPoint Medical B.V.
• Siemens Healthineers
• Therapixel SA
• Volpara Health Technologies Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support